The Alberta Diabetes Institute (ADI) plans on conducting an anti-obesity drug clinical trial for those with rare genetic conditions that contribute to their obesity. The Canadian team will test the effectiveness of setmelanotide (Rhythm Pharmaceutical) on participants...